People | January 10, 2023
GenNext Technologies appoints Dr. John Grant to its Board of Directors
Dr. Grant brings to the table significant BOD governance, global business development, and corporate development expertise
Dr. Grant brings to the table significant BOD governance, global business development, and corporate development expertise
To create leading company developing medicines targeting metalloenzymes
The cash and debt free consideration value is €370 million.
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
Post the sale, Patel family has become the single largest promoter shareholder in the company
Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, and Project X join ARCH as new additional investors
China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production
The company will set-up a pharmaceuticals formulation manufacturing unit with an investment of Rs. 100 crore in Odisha
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
Acquisition expands Merck’s growing hematology portfolio
Subscribe To Our Newsletter & Stay Updated
